Trial ID 21235 COMET | Maryland Oncology Hematology Trial ID 21235 COMET – Maryland Oncology Hematology

Trial ID 21235 COMET

Trial Information - Phase III

A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma

Protocol ID: CNIS793B12301

Sponsor: Novartis Pharmaceuticals Corporation

Status: OPEN TO ENROLLMENT

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Pancreas

Investigator

Juneja MD, Vinni

Status

OPEN TO ENROLLMENT

Sponsor

Novartis Pharmaceuticals Corporation
« Clinical Trails Main

Quality Care Close to Home

View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology